RBC Capital Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) but lowers the price target from $53 to $50.

February 28, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Pliant Therapeutics but lowers the price target from $53 to $50.
The adjustment in price target by RBC Capital, while maintaining an Outperform rating, suggests a continued positive outlook on PLRX but with a slightly moderated growth expectation. This could lead to a neutral short-term impact on the stock as the market digests the revised target alongside the maintained positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100